Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57;Geometric Mean Titers (GMT) of Serum Binding Antibody (bAb) Against SARS-CoV-2 on Day 57;Percentage of Participants With Any AE Leading to Discontinuation of Vaccination;Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 57;Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 57;Percentage of Participants With Serious Adverse Events (SAEs) Until Day 57;Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 57;Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination;Percentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination;Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination;Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination;Percentage of Participants With Unsolicited AEs for 28 Days Following First Vaccination;Percentage of Participants With Unsolicited AEs for 28 Days Following Second Vaccination;Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57

Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57;Geometric Mean Titers (GMT) of Serum Binding Antibody (bAb) Against SARS-CoV-2 on Day 57;Percentage of Participants With Any AE Leading to Discontinuation of Vaccination;Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 57;Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 57;Percentage of Participants With Serious Adverse Events (SAEs) Until Day 57;Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 57;Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination;Percentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination;Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination;Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination;Percentage of Participants With Unsolicited AEs for 28 Days Following First Vaccination;Percentage of Participants With Unsolicited AEs for 28 Days Following Second Vaccination;Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57

Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57;Geometric Mean Titers (GMT) of Serum binding antibody (bAb) Against SARS-CoV-2 on Day 57;Percentage of Participants with Any AE Leading to Discontinuation of Vaccination;Percentage of Participants with Any AE Leading to Participant's Withdrawal from the Trial until Day 57;Percentage of Participants with Medically-Attended Adverse Events (MAAEs) until Day 57;Percentage of Participants with Reported Solicited Local Adverse Events (AEs) for 7 Days Following Each Vaccination;Percentage of Participants with SARS-CoV-2 Infection until Day 57;Percentage of Participants with Serious AE (SAE) until Day 57;Percentage of Participants with Solicited Systemic AEs for 7 Days Following Each Vaccination;Percentage of Participants with Unsolicited AEs for 28 Days After Each Vaccination;Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57

Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57;Geometric Mean Titers (GMT) of Serum binding antibody (bAb) Against SARS-CoV-2 on Day 57;Percentage of Participants with Any AE Leading to Discontinuation of Vaccination;Percentage of Participants with Any AE Leading to Participant's Withdrawal from the Trial until Day 57;Percentage of Participants with Medically-Attended Adverse Events (MAAEs) until Day 57;Percentage of Participants with Reported Solicited Local Adverse Events (AEs) for 7 Days Following Each Vaccination;Percentage of Participants with SARS-CoV-2 Infection until Day 57;Percentage of Participants with Serious AE (SAE) until Day 57;Percentage of Participants with Solicited Systemic AEs for 7 Days Following Each Vaccination;Percentage of Participants with Unsolicited AEs for 28 Days After Each Vaccination;Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57